Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00175916 · ClinicalTrials.gov registry record · Phase 3
Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 853
- Enrollment target
NCT00175916 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 853 participants.
The verdict
NCT00175916, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 853 participants
- Enrollment target
Study Summary
This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment. The study will also evaluate the maintenance of efficacy over time of brivaracetam for subjects with partial onset seizures (POS)/primary generalized seizures (PGS).
Interventions
- DRUG Brivaracetam (ucb 34714)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 853 participants |
| Start Date | 2005-09 |
| Est. Completion | 2019-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00175916
The ClinicalTrials.gov registry entry for NCT00175916 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 853 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brivaracetam (ucb 34714) is the first listed.
NCT00175916 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00175916 about?
NCT00175916 is a clinical study titled "Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy". This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment. The study will also evaluate the maintenance of efficacy over time of brivaracetam for subjec...
What is the current status of trial NCT00175916?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 853 participants. The study started on 2005-09. Estimated completion is 2019-05.
What interventions are being tested in trial NCT00175916?
The interventions under investigation include: Brivaracetam (ucb 34714) (DRUG).
Who is sponsoring clinical trial NCT00175916?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.